[1] MOKDAD AA,LOPEZ AD,SHAHRAZ S,et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010:A systematic analysis[J]. BMC Med,2014,12:145.
|
[2] TAPPER EB,PARIKH ND. Mortality due to cirrhosis and liver cancer in the United States,1999-2016:Observational study[J]. BMJ,2018,362:k2817.
|
[3] WANGJIA ML,LI SB. Hepatology[M]. Beijing:People's Medical Publishing House,2013:630-631.(in Chinese)王家马龙,李绍白.肝脏病学[M].北京:人民卫生出版社,2013:630-631.
|
[4] BAKI JA,TAPPER EB. Contemporary epidemiology of cirrhosis[J]. Curr Treat Options Gastroenterol,2019,17(2):244-253.
|
[5] PALARETI G COSMI B,LEGNANI C,et al. D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism:A management study[J]. Blood,2014,124(2):196-203.
|
[6] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
[7] LYU J,DONG SS,GU HT,et al. TCM syndrome characteristics of portal vein thrombosis in patients with liver cirrhosis and related risk factors[J]. J Clin Hepatol,2019,35(10):2210-2213.(in Chinese)吕靖,董思思,顾宏图,等.肝硬化并发门静脉血栓的危险因素及中医证候特点[J].临床肝胆病杂志,2019,35(10):2210-2213.'
|
[8] QIAN HC,LU ZQ,ZHANG TP. Clinical significance of procalcitonin combined with D-dimer in assessment of the severity of acute cholangitis[J]. J Clin Exp Med,2019,18(18):1949-1952.(in Chinese)钱海超,芦照青,张天鹏.血浆降钙素原与D-二聚体水平在判断急性胆管炎病情严重程度中的临床价值[J].临床和实验医学杂志,2019,18(18):1949-1952.
|
[9] SUN HS,ZHU H,GAO HY,et al. Value of combined detection of tumor markers SCC-Ag,CEA,CYFRA21-1 and Ddimer in early diagnosis of non-small cell lung cancer[J]. J Jilin Univ(Med Edit),2018,44(5):1020-1024.(in Chinese)孙洪帅,朱华,高海燕,等.肿瘤标志物SCC-Ag、CEA、CYFRA21-1和D-二聚体联合检测对非小细胞肺癌的早期诊断价值[J].吉林大学学报(医学版),2018,44(5):1020-1024.
|
[10] LE GAL G,RIGHINI M,WELLS PS. D-dimer for pulmonary embolism[J]. JAMA,2015,313(16):1668-1669.
|
[11] DROLZ A,HORVATITS T,ROEDL K,et al. Coagulation parameters and major bleeding in critically ill patients with cirrhosis[J]. Hepatology,2016,64(2):556-568.
|
[12] RAUTOU PE,VION AC,LUYENDYK JP,et al. Circulating microparticle tissue factor activity is increased in patients with cirrhosis[J]. Hepatology,2014,60(5):1793-1795.
|
[13] LI Y,QI X,LI H,et al. D-dimer level for predicting the inhospital mortality in liver cirrhosis:A retrospective study[J].Exp Ther Med,2017,13(1):285-289.
|
[14] PUGH RN,MURRAY-LYON IM,DAWSON JL,et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg,1973,60(8):646-649.
|
[15] KAMATH PS,WIESNER RH,MALINCHOC M,et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology,2001,33(2):464-470.
|
[16] QI T,ZHU C,LU G,et al. Elevated D-dimer is associated with increased 28-day mortality in acute-on-chronic liver failure in China:A retrospective study[J]. BMC Gastroenterol,2019,19(1):20.
|
[17] WANNHOFF A,MLLER OJ,FRIEDRICH K,et al. Effects of increased von Willebrand factor levels on primary hemostasis in thrombocytopenic patients with liver cirrhosis[J]. PLo S One,2014,9(11):e112583.
|
[18] SMALBERG JH,KOEHLER E,DARWISH MURAD S,et al. Fibrinogenγ'and variation in fibrinogen gamma genes in the etiology of portal vein thrombosis[J]. Thromb Haemost,2013,109(3):558-560.
|
[19] SENZOLO M,SIMIONI P,ANDRIULLI A. Screening and treatment of portal vein thrombosis in cirrhosis[J]. Dig Liver Dis,2017,49(2):228-229.
|
[20] XIONG JP,PENG YY,ZHANG YX. Screening for differentially expressed proteins in patients with liver cirrhosis complicated by portal vein thrombosis[J]. J Clin Hepatol,2018,34(1):112-117.(in Chinese)熊静平,彭媛媛,张跃新.肝硬化合并门静脉血栓患者的差异蛋白筛选[J].临床肝胆病杂志,2018,34(1):112-117.
|
[21] CUI S,FU Z,FENG Y,et al. The disseminated intravascular coagulation score is a novel predictor for portal vein thrombosis in cirrhotic patients with hepatitis B[J]. Thromb Res,2018,161:7-11.
|
[22] WEI Y,CHEN X,SHEN H,et al. P-selectin level at first and third day after portal hypertensive splenectomy for early prediction of portal vein thrombosis in patients with cirrhosis[J].Clin Appl Thromb Hemost,2018,24(9 Suppl):76s-83s.
|
[23] MALAGUARNERA M,LATTERI S,BERTINO G,et al. D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis[J]. Clin Exp Gastroenterol,2018,11:373-380.
|
[24] DAI J,QI X,LI H,et al. Role of D-dimer in the development of portal vein thrombosis in liver cirrhosis:A Meta-analysis[J]. Saudi J Gastroenterol,2015,21(3):165-174.
|
[25] MALAGUARNERA G,VACANTE M,DRAGO F,et al. Endozepine-4 levels are increased in hepatic coma[J]. World J Gastroenterol,2015,21(30):9103-9110.
|
1. | 张冰荫 ,李辉 ,范瑾 ,杨云 ,贾笑迪 ,杨幸幸 . D-二聚体、C肽水平结合经皮氧分压在糖尿病周围神经病变中诊断价值. 分子诊断与治疗杂志. 2024(05): 926-929 . ![]() | |
2. | 朱志峰,金剑,陶伟民,徐振东,张海. 血清D-二聚体消除动力学模型构建对静脉血栓栓塞的预测价值. 中国医药导报. 2024(10): 77-80 . ![]() | |
3. | 刘悦,吴翰林,佟武强,许静. 自身抗体和D-二聚体检测评估慢性乙型肝炎及乙型肝炎肝硬化患者预后的价值. 诊断学理论与实践. 2024(02): 173-179 . ![]() | |
4. | 周阳丹,曹运强. 肝硬化合并自发性细菌性腹膜炎血浆PCT、PGE2、D-D、NGAL水平变化. 临床消化病杂志. 2023(01): 34-37 . ![]() | |
5. | 蒋靓星,朱平,谷锦,蒋娜. 糖尿病患者周围神经病变患者炎性因子与D-二聚体的相关性研究. 长春中医药大学学报. 2023(02): 197-200 . ![]() | |
6. | 张珊,陈松海,刘妍,王春艳,付懿铭,陆荫英,纪冬,陈国凤. 非酒精性脂肪性肝病对乙肝病毒相关肝细胞癌患者生存的影响. 解放军医学杂志. 2023(02): 157-162 . ![]() | |
7. | 武幸,张秀军,薛源,薛峰,徐尧,冯静云,陈菲菲. 肝硬化消化道出血患者血抗凝血酶Ⅲ和D-二聚体水平变化及临床意义. 中国肝脏病杂志(电子版). 2023(01): 56-61 . ![]() | |
8. | 杨春霞. D-二聚体检测及临床应用研究. 医学信息. 2023(12): 189-192 . ![]() | |
9. | 尹明月,许觉彬,季沈杰. 肝硬化患者凝血4项与D2聚体的检测分析. 系统医学. 2023(13): 63-65+69 . ![]() | |
10. | 邱建华. PLT联合凝血功能检测对早期肝硬化的诊断价值分析. 现代诊断与治疗. 2023(22): 3433-3435 . ![]() | |
11. | 蒙增萍,翟丽琼,李燚,陈驰,刘咏梅. 肝硬化患者Child-Pugh分级与凝血4项、D-二聚体的关系. 贵州医科大学学报. 2022(01): 66-71+78 . ![]() | |
12. | 张鹭坚,蔡梅真. 肝炎肝硬化患者血清总胆固醇、血清白蛋白与胆碱酯酶水平在肝功能评估中的应用. 吉林医学. 2022(02): 482-484 . ![]() | |
13. | 李芳芳,李娟,余真君. 乙肝相关性肝硬化患者肝功能Child-Pugh分级及相关生化指标与血清中HBV DNA水平的相关性. 中国现代医生. 2022(03): 108-111 . ![]() | |
14. | 汪伟,温巧生. 凝血功能指标与肝硬化患者肝储备功能及上消化道大出血的关系. 医学研究生学报. 2022(04): 388-393 . ![]() | |
15. | 王可欣,纪冬. 乙型肝炎病毒与肝细胞癌关系研究进展. 传染病信息. 2022(02): 166-171 . ![]() | |
16. | 李晓艳. D-二聚体在肝硬化患者临床检验中的应用价值探讨. 中国现代药物应用. 2022(08): 62-64 . ![]() | |
17. | 陈松海,王春艳,郭畅,张珊,邓亚,陆荫英,纪冬. 预测HBV相关肝细胞癌生存的列线图模型的建立. 临床肝胆病杂志. 2022(07): 1566-1571 . ![]() | |
18. | 赵英妹,聂红明,张珏,黄燕. 肝硬化患者凝血五项的测定及其临床意义. 诊断学理论与实践. 2021(05): 480-483 . ![]() | |
19. | 王雪刚,梁锦峰,武海波. 替比夫定、阿德福韦酯联用与恩替卡韦单药治疗失代偿期乙肝肝硬化效果比较. 黑龙江医药. 2020(04): 831-833 . ![]() | |
20. | 王雪刚,梁锦峰,杨澍,武海波. 恩替卡韦治疗代偿期乙肝肝硬化患者预后效果观察. 航空航天医学杂志. 2020(08): 913-915 . ![]() | |
21. | 何伟锋,吴少彬,万婷. 乙肝肝硬化患者体成分分析在评估患者预后及生存率中的应用价值. 临床医学研究与实践. 2020(27): 122-124 . ![]() | |
22. | 李小利,杨会科. 血浆D–D与凝血四项检测对肝硬化患者的诊断意义. 深圳中西医结合杂志. 2020(17): 82-83 . ![]() | |
23. | 马欣,朱姣姣. 睡前1h加餐对老年乙肝肝硬化合并糖尿病患者糖代谢指标和肝功能指标的影响. 临床护理杂志. 2020(05): 33-35 . ![]() |